TLC590
Metabolic disorders
Phase 2Active
Key Facts
About Taiwan Liposome Company
Taiwanese biotech leveraging next‑gen lipid delivery for pain, metabolic and cell‑therapy medicines.
View full company profileTherapeutic Areas
Other Metabolic disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Novel GLP-1 Receptor Agonist | Lupin | Pre-clinical/Clinical |
| Undisclosed Metabolic Program | Kallyope | Discovery |
| Metabolic Disorders Program | Seragon Biosciences | Pre-clinical |
| PPARγ Program | Micar Innovation | Discovery |
| Pancreas-Targeting Capsids | rAAVen Therapeutics | Pre-clinical |
| IVL-001 | InVirtuoLabs | Discovery |
| AmorphOX GLP-1 | Orexo | Preclinical |
| Amylin Program | Orion Biotechnology | Discovery |
| Not specifically disclosed on public website | Taisho Pharmaceutical | Various |